Donna Hansel, MD, PhD, of University of California, San Diego, School of Medicine, explains her use of human bladder cancer cells in her research.
Donna Hansel, MD, PhD, of University of California, San Diego, School of Medicine, explains her use of human bladder cancer cells in her research.
Transcript
A unique aspect of your lab is the use of human bladder specimens. Can you explain how you use them?
As a pathologist, we are often involved in dissecting specimens as they come out of the operating room. A lot of what we see when we open the bladder and also as we see it under the microscope really helps me at least formulate ideas about what’s happening with invasion and the spread of bladder cancer cells. What we try to do, especially because my lab studies invasion, is to say, "okay, well, we have all these wonderful in vitro techniques that we can use in the laboratory, but is there a way to use ex vivo techniques? Using actual human bladder cancer cells and using the background bladder matrix that the cells invade into?" Having done that, we’ve developed ex-plant models, primary culture models, things where we can take the cells and take the matrix that they invade into and modulate both of those to better understand how the interaction of cancer cells with the environment permits cancer growth.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC
February 18th 2025Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell carcinoma (RCC).
Read More